Navela (Levonorgestrel)

Levonorgestrel, the active ingredient in Navela, is a progestogen presented as an oral tablet for systemic use. It is employed to prevent pregnancy, including emergency contraception, by inhibiting ovulation and altering the uterine lining. It is indicated for women of reproductive age who require a rapid, non‑hormonal method to avoid unintended pregnancy after unprotected intercourse. GNH USA supplies Navela as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, with a focus on quality assurance and regulatory compliance across EU and global markets.

Levonorgestrel is employed within hormonal contraceptive strategies to prevent pregnancy by suppressing ovulation and modifying the uterine environment, offering both emergency and ongoing protection. - Emergency contraception: prevents pregnancy when taken within 72 hours after unprotected intercourse. - Progestogen‑only contraception: provides ongoing daily prevention of ovulation for women seeking a single‑hormone oral method. - Post‑coital pregnancy prevention: alters the endometrial lining to reduce the likelihood of implantation after fertilization. - Menstrual cycle management: can be used off‑label to delay the onset of menstruation when needed. - Pregnancy prevention: serves as a reliable option for women desiring immediate protection against unintended pregnancy.

Levonorgestrel may cause a range of adverse reactions, most of which are mild and transient. Common Side Effects: - Nausea: mild to moderate stomach upset. - Headache: occasional tension‑type headache. - Breast tenderness: temporary discomfort in the breasts. - Irregular bleeding: spotting or changes in menstrual flow. Serious or Rare Side Effects: - Severe allergic reaction (anaphylaxis): swelling, rash, difficulty breathing. - Thromboembolic events: blood clots in veins or arteries. - Liver dysfunction: jaundice, elevated liver enzymes.

Before prescribing Navela, clinicians should evaluate patient history and potential risk factors. - Assess medical history: confirm no contraindications such as active thromboembolic disease. - Avoid use in: known hypersensitivity to levonorgestrel or any excipients. - Consider hepatic function: use with caution in severe liver disease. - Monitor menstrual changes: advise patients about possible spotting or delayed periods. - Pregnancy testing: ensure patient is not already pregnant before administration. Store at ambient temperature: keep below 25 °C, in original packaging, protected from moisture and light.

Levonorgestrel can interact with other medicines, affecting its efficacy or safety. Major Interactions (Avoid): - Rifampin and other enzyme inducers: may reduce contraceptive effectiveness. - Antiepileptic drugs (e.g., carbamazepine, phenytoin): may lower plasma levonorgestrel levels. - Protease inhibitor antiretrovirals (e.g., ritonavir): may increase levonorgestrel exposure and side‑effects. Moderate Interactions (Monitor Closely): - Antifungal azoles (e.g., ketoconazole): may increase levonorgestrel concentrations. - St. John’s wort: may decrease contraceptive effectiveness. - Hormonal therapies (e.g., combined oral contraceptives): may have additive progestogenic effects.